As indicated in Table 1, this includes studies showing that the upregulation of AnxA6 is an indicator of the progression of ovarian carcinomas [107], women’s thyroid cancer [108], polycystic ovarian syndrome [109], pancreatic cancer [96] and esophageal adenocarcinoma [110]. Here, ANXA6 is linked to thyroid cancer.